Summary
The pharmacokinetics of flecainide and its two sequential metabolites, both free and conjugated, its pharmacodynamics, and the influence of simultaneously administered quinine, have been studied in 10 healthy subjects. The study comprised two, 48-h open phases at an interval of 1 week. Flecainide acetate 150 mg was given as a 30-min i.v. infusion and quinine sulphate orally 500 mg×3 over 24 h.
Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.2 vs 7.6 ml · kg−1 · min−1), thus increasing the elimination half-life (9.6 vs 11.5 h). The amount of flecainide transformed to its first, meta-O-dealkylated metabolite (MODF) fell with no change in the renal excretion of the latter, either in its free or conjugated forms.
This finding, in association with a fall in amount of the second, meta-O-dealkylated lactam metabolite (MODLF) recovered in its conjugated forms in the urine, suggests that quinine inhibits both the first and the second steps of the sequential metabolism of flecainide.
When the subjects received quinine in addition to flecainide, the PR interval in the ECG was slightly more prolonged than with flecainide alone. Due to the study design, an effect of quinine per se and the consequence of increased serum flecainide levels could not be distinguished.
Similar content being viewed by others
References
Goy JJ, Kappenberger L (1987) Flecainide acetate in supraventricular arrhythmias. J Electrophysiol 1: 113–119
Holmes B, Heel RC (1985) Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 1–33
Shin S-G, Juan D, Rammohan M (1988) Theophylline pharmacokinetics in normal elderly subjects. Clin Pharmacol Ther 44: 522–530
McQuinn RL, Quarfoth GJ, Johnson JD, Banitt EH, Pathre SV, Chang SF, Ober RE, Conard GJ (1984) Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab Disposit 12: 414–420
Conard GJ, Ober RE (1984) Metabolism of flecainide. Am J Cardiol 53: 41B-51B
Gillis AM, Kates RE (1984) Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet 9: 375–403
Muhiddin KA, Johnston A, Turner P (1984) The influence of urinary pH on flecainide excretion and its serum pharmacokinetics. Br J Clin Pharmacol 17: 447–451
Johnston A, Warrington S, Turner P (1985) Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. Br J Clin Pharmacol 20: 333–338
Tjandra-Maga TB, Verbesselt R, Van Hecken A, Mullie A, De Schepper PJ (1986) Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. Br J Clin Pharmacol 22: 309–316
Cavalli A, Maggioni AP, Marchi S, Volpi A, Latini R (1988) Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias. Clin Pharmacokinet 14: 187–188
Williams AJ, McQuinn RL, Walls J (1988) Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther 43: 449–455
Forland SC, Burgess E, Blair AD, Cutler RE, Kvam DC, Weeks CE, Fox JM, Conard GJ (1988) Oral flecainide pharmacokinetics in patients with impaired renal function. J Clin Pharmacol 28: 259–267
McQuinn RL, Pentikäinen PJ, Chang SF, Conard GJ (1988) Pharmacokinetics of flecainide in patients with cirrhosis of the liver. Clin Pharmacol Ther 44: 566–572
Braun J, Kollert JR, Gessler U, Becker JU (1987) Failure of haemoperfusion to reduce flecainide intoxication. Med Toxicol 2: 463–467
Bailie GR, Waldek S (1988) Pharmacokinetics of flecainide in a patient undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol Ther 13: 121–124
Borgeat A, Biollaz J, Freymond B, Bayer-Berger M, Chioléro R (1988) Hemofiltration clearance of flecainide in a patient with acute renal failure. Intensive Care Med 14: 236–237
Lewis GP, Holtzman JL (1984) Interaction of flecainide with digoxin and propranolol. Am J Cardiol 53: 52B-57B
Shea P, Lal R, Kim SS, Schechtman K, Ruffy R (1986) Flecainide and amiodarone interaction. J Am Coll Cardiol 7: 1127–1130
Tjandra-Maga TB, Van Hecken A, Van Melle P, Verbesselt R, De Schepper PJ (1986) Altered pharmacokinetics of oral flecainide by cimetidine. Br J Clin Pharmacol 22: 108–110
Cafruny EJ (1977) Renal tubular handling of drugs. Am J Med 62: 490–496
Rennick BR (1981) Renal tubule transport of organic cations. Am J Physiol 240: F83-F89
Rennick BR (1972) Renal excretion of drugs: tubular transport and metabolism. Ann Rev Pharmacol 12: 141–156
Torretti G, Weiner IM, Mudge GH (1962) Renal tubular secretion and reabsortion of organic bases in the dog. J Clin Invest 41: 793–804
Weiner IM (1985) Organic acids and bases and uric acid. In: Seldin DW, Giebisch G (ed) The kidney: physiology and pathophysiology. Raven Press, New York, pp 1703–1724
Weiner IM, Roth L (1981) Renal excretion of cimetidine. J Pharmacol Exp Ther 216: 516–520
Christian CD, Meredith CG, Speeg KV (1984) Cimetidine inhibits renal procainamide clearance. Clin Pharmacol Ther 36: 221–227
Somogyi A, McLean A, Heinzow B (1983) Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol 25: 339–345
McKinney TD, Speeg KV (1982) Cimetidine and procainamide secretion by proximal tubules in vitro. Am J Physiol 242: F672-F680
Munafo A, Biollaz J (1989) High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serum. J Chromatogr Biomed Appl 490: 450–457
Gomeni R (1988) Siphar, version 3. SIMED, Créteil, France
van Ginneken CAM, Russel FGM (1989) Saturable pharmacokinetics in the renal excretion of drugs. Clin Pharmacokinet 16: 38–54
Giacomini KM, Hsyu PH, Gisclon LG (1988) Renal transport of drugs: An overview of methodology with application to cimetidine. Pharm Res 5: 465–471
Rennick BR, Ziemniak J, Smith I, Taylor M, Acara M (1984) Tubular transport and metabolism of cimetidine in chicken kidneys. J Pharmacol Exp Ther 228: 387–392
Notterman DA, Drayer DE, Metakis L, Reidenberg MM (1986) Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 40: 511–517
White NJ, Chanthavanich P, Krishna S, Bunch C, Silamut K (1983) Quinine disposition kinetics. Br J Clin Pharmacol 16: 399–403
Suphakawanich W, Thithapandha A (1987) Inhibition of hepatic drug metabolism by quinine. Asia Pac J Pharmacol 2: 241–247
Beckmann J, Hertrampf R, Gundert-Remy U, Mikus G, Gross AS, Eichelbaum M (1988) Is there a genetic factor in flecainide toxicity? Br Med J 297: 1316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Munafo, A., Reymond-Michel, G. & Biollaz, J. Altered flecainide disposition in healthy volunteers taking quinine. Eur J Clin Pharmacol 38, 269–273 (1990). https://doi.org/10.1007/BF00315029
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315029